BioSpace News Archive

Shionogi Granted New Technology Add-on Payment For FETROJA ® (Cefiderocol) by CMS Add-on Payment to Reimburse Hospitals up to 75 percent of the cost of FETROJA in Hospital Inpatient Setting OSAKA, Japan and FLORHAM PARK, N.J.--( BUSINESS WIRE )-- Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for FETROJA ® (cefiderocol) whe

Alphamab Oncology (stock code: 9966 HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to KN046, a recombinant humanized PD-L1/CTLA-4 bispecific antibody developed by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“Jiangsu Alphamab”), a wholly-owned subsidiary of the company, f

CannaGlobal Canada Co. Inc., Sansero Life Sciences Inc., and Rise Wellness this week announced the completion of their amalgamation to form CannaGlobal Wellness, a global psychedelics leader focused on psilocybin and other natural compounds to promote emotional, mental, and physical wellness. Sansero Life Sciences is developing psilocybin-based pharmaceutical products to treat mental health conditions, and Rise Wellness has

Technology applies “clean room” principles to create a safe, breathable environment for the nose and mouth while filtering exhaled breath

Grant will support online and one-on-one efforts to enroll millions of eligible individuals into benefits The National Council on Aging (NCOA), a trusted national leader working to ensure that every person can age well, has been awarded a 5-year, $57.5 million grant from the U.S. Administration fo

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases, today announced updated timing for the presentation of results from Part 1 of the Phase 2 PASADENA study of prasinezumab in early Parkinson’s disease. As previously announced, results from Part 1 of the Phase 2 PASADENA study

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases, today announced that the company will make presentations related to its lead product candidate, LYR-210, at the 66 th Annual Meeting of the American Rhinologic Society (ARS), taking place as a

Misonix, Inc. (Nasdaq: MSON) (“Misonix” or the “Company”), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2020 fourth quarter and full fiscal year ended June 30, 2020 as summarized below: Three Months Ended Year Ended June 30, June 30, 2020 2019 2020

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging unparalleled insights into protein motion, today announced the first patient has been dosed in a first-in-human clinical trial of RLY-4008 enriched for patients with intrahepatic cholangiocarcinoma (ICC) and other advanced solid tumors harboring a fibroblast growth factor receptor 2 (FGFR2) alteration. RL

On August 4 th , 2020 Premier Health of America Inc. (formerly known as Physinorth Acquisition Corporation Inc.) (TSXV: PHA) (the “ Corporation ” or “ Premier Health ”), a leading Canadian Healthtech company, announced that on August 3 rd , 2020, it had entered into a share purchase agreement (the “ SPA ”) to acquire 100% of the issued and outstanding shares of 9104-8306 Québec Inc. d.b.a Code Bleu Placement en Santé (“ Code Bleu ”), (the “ Transact